Skip to main content
OpenTrials
Completed

NCT Number: NCT01656759

Use of a Novel Fibrin Sealant in Total Knee Arthroplasty

Applying a fibrin spray, after knee device implantation, will help in reducing patient blood loss and decrease the drop in both hemoglobin and hematocrit levels. Also, with decreased blood loss there should be a reduced need for blood transfusions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Rush Oak Park Hospital

Oak Park, Illinois, 60304, United States

About this study

Study Design

Study design and control methods:

This study is designed as a prospective, randomized, double-blinded controlled clinical trial to compare the effect of a fibrin spray applied to the surgical wound as compared to patients not receiving the fibrin spray.

Treatment group:

The subjects will be randomly assigned to the fibrin treatment group or to the control group at the time of the surgery via the opening of a randomly selected sealed envelope. The patient and the independent reviewer will be blinded as to which treatment group the patient is assigned to. This information will be linked to a confidential database for later review by the principal investigator.

Treatment allocation:

All eligible patients (i.e., meeting inclusion criteria and no exclusion criteria) will be treated and observed per the research protocol. All patients will maintain the right to refuse participation and receive a specific treatment of the study if desired.

Trial Population:

The target sample size is 70 patients for both the treatment and control groups (140 total) with each group split evenly between males and females. There will be one actively enrolling surgeon (Dr. Brett Levine). The goal is to enroll a total of 140 subjects experiencing joint pain that warrants a Total knee arthroplasty (TKA). The specific diagnosis for the joint pain will not direct the subjects' assignment or eligibility at the time of surgery. All 140 patients will be enrolled from the office of the primary investigator (Dr. Brett Levine). All indications for TKA will be included unless one of the exclusion criteria is met.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must be male or female of any race
  • Ages 18-80 years old
  • Patients must be undergoing an elective, primary knee arthroplasty performed by the principal investigator

Exclusion criteria

  • Allergy or intolerance to the study materials
  • Surgical intervention during the past month for the treatment of the painful joint or its underlying etiology
  • History of previous surgeries on the affected joint including previous arthroscopy (open surgeries)
  • Women that are pregnant or may become pregnant
  • Patient declines to participate

Treatment and study plan

Evicel Fibrin Spray

Drug

10cc syringe dose, once at the end of TKA

Other names: Produced by OMRIX Biopharmaceuticals, Ltd.

Primary outcomes

  1. Primary--Percent Change of Pre- to Post-Operative Hemoglobin

    Time frame: Pre-operative to 1 month

    Pre-operative hemoglobin values from routine CBC no earlier than 1 month prior to surgery were compared to post-operative hemoglobin values from routine CBC after surgery.

  2. Total Blood Loss

    Time frame: Collected during surgery and in first 2-3 days after surgery

    Combination of intraoperative and postoperative blood loss for participants.

Secondary outcomes

  1. Total Transfusions

    Time frame: 3 days

    The number of transfusions each patient receives during their postoperative hospitalization.

  2. Postoperative Blood Loss

    Time frame: 3 days

    Measured as drainage output from postoperative drains during hospitalization.

Sponsors and collaborators

Lead sponsor

Rush University Medical Center

Other

Registry information

Official study title

Use of a Novel Fibrin Sealant in Total Knee Arthroplasty: A Prospective Randomized Controlled Clinical Trial

Important dates

Study start
2012
Primary completion
2014
Study completion
2015
First posted
Aug 3, 2012
Registry last updated
Feb 9, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.